2024
Progesterone Receptor Status predicts Aggressiveness of Human Endometriotic lesions in Murine Avatars
Flores V, Sahin C, Taylor H. Progesterone Receptor Status predicts Aggressiveness of Human Endometriotic lesions in Murine Avatars. F&S Science 2024 PMID: 39393571, DOI: 10.1016/j.xfss.2024.10.004.Peer-Reviewed Original ResearchProgestin-based therapyAggressive forms of endometriosisPR lesionsProgesterone receptorGnRH antagonistMedroxyprogesterone acetatePR statusEndometriotic lesionsAggressive formResponse to MPAResponse to medical therapyPost-treatment sizeProgesterone receptor statusHuman endometriotic lesionsResponse to progestinsChronic gynecological diseaseDaily subcutaneous injectionsReproductive-age womenMouse xenograft modelResponse to medicationEndometrioma lesionsReceptor statusHormone suppressionPR expressionClinical response
2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. New England Journal Of Medicine 2017, 377: 28-40. PMID: 28525302, DOI: 10.1056/nejmoa1700089.Peer-Reviewed Original ResearchConceptsNonmenstrual pelvic painEndometriosis-associated painPelvic painClinical responsePercentage of womenPlacebo groupEnd pointPrimary efficacy end pointSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOral GnRH antagonistRescue analgesic agentsEfficacy end pointPrimary end pointPhase 3 trialClinical response criteriaEstrogen-dependent conditionDaily electronic diaryBone mineral densityProportion of womenCorresponding percentagesEndometrial findingsEstrogen suppressionPain scoresHot flushes